Eli Lilly (LLY) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Eli Lilly (LLY) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
14.49% |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
168.07% |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
-52.40% |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
-45.93% |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
-182.77% |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
5.14% |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
53.69% |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
- |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
8.81% |
| 10 |
Novartis Ag |
108.28 Bn |
107.60 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
168.07% |
| Dec 31, 2025 |
50.52% |
| Sep 30, 2025 |
475.34% |
| Jun 30, 2025 |
90.78% |
| Mar 31, 2025 |
23.01% |
| Dec 31, 2024 |
101.43% |
| Sep 30, 2024 |
1,790.42% |
| Jun 30, 2024 |
68.27% |
| Mar 31, 2024 |
66.77% |
| Dec 31, 2023 |
12.98% |
| Sep 30, 2023 |
-103.95% |
| Jun 30, 2023 |
85.11% |
| Mar 31, 2023 |
-29.32% |
| Dec 31, 2022 |
12.26% |
| Sep 30, 2022 |
30.77% |
| Jun 30, 2022 |
-31.48% |
| Mar 31, 2022 |
40.40% |
| Mar 31, 2019 |
7,231.67% |
| Dec 31, 2018 |
100.24% |
| Sep 30, 2018 |
-89.94% |
